Taylor Wessing advises Azenta Life Sciences on the acquisition of the Barkey Group

Under the lead of M&A Salary Partner Stephan Doom and M&A Partner Michael Stein, Taylor Wessing has advised US-based Azenta, Inc. (NASDAQ: AZTA) on the acquisition of medical technology company Barkey including all of its subsidiaries. The purchase price is approximately € 80 million. The transaction is expected to close in early July 2022.

Azenta is based in Chelmsford, near Boston/Massachusetts, and is a leading provider of cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally.

Barkey, based in Leopoldshöhe near Bielefeld, Germany, has more than four decades of experience in automated thawing of plasma, blood and stem cells and has focused on applications in cell and gene therapy. Barkey's Plasmatherm product is an automated device for thawing cells that is approved by the U.S. Food and Drug Administration (FDA) as a medical device for clinical use.

Taylor Wessing Germany: Lead Stephan Doom (Salary Partner) and Michael Stein (Partner), Dr. Vinia Tepel (Associate, Hamburg), all Corporate/M&A; Claus Goedecke (Partner, Finance), Arno Gotting (Salary Partner), Nils Schulze-Brüggemann (Associate), both Commercial; Dr. Jan Grawe (Salary Partner), Dr. Sara Thienhaus (Associate) both Employment; Svenja-Ariane Maucher (Partner), Matthias Brenner (Associate), both IT; Dr. Stefan Fröhlich (Salary Partner), Henrik Lerchl (Associate) both IP-Law; Rudi Hasenberg (Salary Partner, Tax), Dr. Andrea Sautter (Salary Partner), Irina Rebin (Associate), Tobias Baus (Associate,) all Life Sciences Regulatory, Munich; Dr. Marco Hartmann-Rüppel (Partner, Hamburg), Louisa Nowalder (Associate, Düsseldorf), both Competition, EU & Trade; Nikolaus Vaerst (Senior Associate, Real Estate, Hamburg); all Frankfurt, unless otherwise stated.